Stable Clear-Almost Clear Response is Sustained up to 3 Years in Patients with Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 25];9(6):s599. Available from: https://skin.dermsquared.com/skin/article/view/3832